Martin E. Gutierrez, MD Director, Phase I Program, Co-Chair of Thoracic Oncology, John Theurer Cancer Center and Hackensack Meridian Health explains his take on how he would treat 1nd line patients who received Keytruda or other PD-L1 targeting agents as their 1st line therapy.
2nd Line Treatment Options Following 1st Line PD-L1 Targeting Agents
